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Abstract: Alpha-1 antitrypsin (A1AT or AAT) is a serine protease inhibitor (PI) which, when present at low levels, 
can cause chronic obstructive pulmonary disease (COPD) and liver disease in both children and adults. Several 
mutations within the SERPINA1 gene have been found to cause this deficiency. The most common variants are 
PI*Z and PI*S, each caused by a single nucleotide polymorphism (SNP). We describe a real time polymerase 
chain reaction (PCR) assay for the rapid genotyping of these polymorphisms. DNA was extracted from fourteen 
EDTA-anticoagulated whole blood samples using the Qiagen EZ1 blood extraction kit. SNP genotyping was 
performed using primer/probe sets purchased from Applied Biosystems. These were evaluated for performance 
and assay conditions on the Applied Biosystems 7500 FAST System. The genotypes of these samples were 
compared with their phenotype results from isoelectric focusing assays, which were performed by an independent 
reference laboratory. In addition, twenty samples that were previously genotyped at another laboratory were 
obtained for accuracy studies. Thirty-four samples were tested; five genotypes were represented and the assay 
was able to discriminate these successfully. Only one genotype could not be correlated with its phenotype result, 
as the phenotype was reported as an “unidentified allele”. All other genotyping results were concordant with 
previously determined genotypes and phenotypes. We describe a rapid real time PCR assay that is suitable for 
clinical use in genotyping AAT alleles and which can be used as the initial step in A1AT testing algorithms. 
 
Key words: Real-time PCR, alpha-1 antitrypsin, molecular diagnostics, serine protease inhibitor, chronic 
obstructive pulmonary disease (COPD), single nucleotide polymorphism (SNP), genotyping 
 
 
 
 
Introduction 
 
Alpha-1-antitrypsin (AAT) deficiency is an 
inherited disorder involving mutations in the 
SERPINA1 (SERine Proteinase INhibitor A1) 
gene and is characterized by low levels of 
circulating AAT protein, resulting in an 
increased risk for development of pulmonary 
emphysema and liver disease [1, 2].  AAT is a 
serine protease inhibitor (PI) that functions to 
protect the lungs from neutrophil elastase, an 
enzyme released from neutrophils triggered in 
response to pathogens that enter the lungs 
[3].  AAT is constitutively produced in the liver 
and its expression is up-regulated during 
inflammation and infection.  Mutations in the 
SERPINA1 gene can result in both early onset 
chronic obstructive pulmonary disease (COPD), 
caused by neutrophil elastase attacking the 
lung, and liver cirrhosis, caused by mutated 
AAT protein that accumulates in the rough 
endoplasmic reticulum of hepatocytes [4, 5]. 
 
The SERPINA1 gene, referred to as the PI 
locus, is a highly pleomorphic gene located at 
14q31-32.3 [6-8].  It is 12.2 kb and contains 
seven exons and six introns.  Of the exons, 
four are coding and three are noncoding [9].  
While AAT displays a significant amount of 
heterogeneity, many of the described genetic 
variants do not affect expression or function of 
this protein [9, 10].  Alleles that result in 
deficient amounts of protein in the circulation, 
degraded protein with no function (null), or 
dysfunctional protein with lower activity levels 
have been identified [10].  The most common 
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alleles in the general population are PI*M, 
PI*S and PI*Z.  The M, S, and Z nomenclature 
derives from the migration velocity of each of 
these variants in starch-gel electrophoresis; M 
migrates at a medium velocity; S, is slow, and 
Z is very slow [11].  The M allele (and two 
common subvariants, M1 and M2) is 
considered the wild-type, or “normal variant”, 
and is associated with normal levels of AAT in 
the plasma; it is the most common in the 
general population [1, 12].  The most common 
variant associated with clinical disease is PI*Z 
allele which results from a G to an A transition 
at nucleotide position 11940 in exon 5 and 
leads to a glutamic acid to lysine substitution 
at amino acid 366 (E366K; rs28929474).  The 
PI*S allele results from an A to T transversion 
at nucleotide position 9628 in exon 3 and 
leads to a glutamic acid to valine substitution 
at amino acid 288 (E288V; rs17580) [13, 14].  
Older literature, which uses an amino acid 
numbering convention based on the mature, 
processed protein, refers to these mutations 
as E342K and E264V, respectively.  A 
genotype of ZZ or SZ can cause clinical AAT 
deficiency, but the homozygous Z genotype 
typically results in the most severe clinical 
phenotype. This is due to the fact that 85% of 
the resultant PI*Z protein accumulates in the 
endoplasmic reticulum of the hepatocytes 
(Table 1) [15]. 
 
Currently, diagnostic laboratory tests for AAT 
deficiency include measurement of the 
circulating AAT protein level, by immunoassay, 
AAT protein phenotyping by isoelectric focusing 
(IEF), genotyping or sequencing of SERPINA1, 
and evaluation of the AAT protein function, 
aimed at detecting dysfunctional alleles that 
produce proper protein amounts.  Normal AAT 
levels in an adult are >104 mg/dL, but 
patients with AAT deficiency have levels 
between 15-75% of normal depending on their 
genotype [16].  Individuals with pulmonary 
symptoms and with AAT levels less than 60 
mg/dl are typically eligible for replacement 
therapy with recombinant AAT protein [17]. 
 
This study describes the detection of the most 
common variants (M, Z, and S) of the 
SERPINA1 gene using a real time PCR assay 
and Taqman probes in patient samples that 
were previously tested by phenotyping and/or 
genotyping. 
 
Materials and methods 
 
Specimens   
 
DNA was extracted from fourteen EDTA-
anticoagulated whole blood samples using the 
Qiagen EZ1 automated system.  Concurrently, 
the plasma from these samples was collected 
and sent to a reference laboratory for IEF 
phenotyping.  In addition, DNA from twenty 
blinded samples that were previously 
genotyped at another institution (Mayo Clinic, 
Rochester, MN) was used for test validation.  
 
Genotyping  
 
All samples were genotyped using an allelic 
discrimination assay on the Applied Bio-
systems 7500 FAST Real Time PCR instrument 
 Table 1. Genetic characteristics of AAT  
• SERPINA1  Gene 
• 14q31-32.3 
• 12.2kb long, 7 exons and 6 introns 
• Protein = 395 amino acids 
• PI*M  allele  
•  Wild Type 
• PI*S  allele 
• A>T Glu288Val 
• Exon 3 
• Misfolding of amino acid causing low serum levels of A1AT  
• PI*Z allele  
• G>A Glu366Lys 
• Exon 5 
• Conformational change in protein causing hepatocyte death and liver disease 
• Other variants: QO (null allele), M-Malton and multiple other SNPs 
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with Taqman® probes. For the PI*S allele, a 
TaqMan® Pre-Designed SNP Genotyping Assay 
was purchased from Applied Biosystems (ABI) 
(assay ID: C_594695_20); for the PI*Z allele, 
a TaqMan® Custom SNP Genotyping Assay was 
purchased.  For the custom assay, primers and 
probes based on the PI*S target sequence 
were designed using the Custom TaqMan® 
Assay Design Tool (Applied Biosystems) (Table 
2).  Both the pre-designed and the custom 
assays included primers and fluorescently 
labeled (FAM and VIC) MGB™ probes for 
detection of both the wild-type and variant 
alleles. 
 
All samples were genotyped using the Allelic 
Discrimination assay on the Applied Bio-
systems 7500 FAST Real-Time PCR System.  
Cycling conditions were as follows: 95°C for 
10 min; 50 cycles of 92°C for 15 sec and 
60°C for 90 sec.  Fluorescence was detected 
during the 60°C annealing step of each PCR 
cycle. 
 
Results 
 
Using the allelic discrimination analysis 
method on the AB 7500 FAST, we were able to 
differentiate wild type, heterozygous and 
homozygous alleles based on specific probe 
hybridizations (Figure 1).  An initial evaluation 
of the primer/probe sets identified for 
genotyping included dilution of known mutant 
DNAs.  As expected, the CT values corres-
ponded to the amount of starting DNA and 
showed that the assay was able to detect a 
genotype even with very low concentrations of 
starting DNA (Table 3). 
  
Of the 14 patient samples collected at our 
medical center, 11 were homozygous non-S, 
non-Z genotype, 2 were heterozygous (non-S, 
non-Z)Z, and 1 was heterozygous (non-S, non-
Z)S.  No homozygous mutant (Z or S) or 
heterozygous mutant (SZ) genotypes were 
detected.  The genotypes of the extracted DNA 
samples from the Mayo Clinic were as follows: 
5 homozygous non-S, non-Z, 12 heterozygous 
(6 (non-S, non-Z)Z and 6 (non-S, non-Z)S), 2 
presumably compound heterozygous, and 1 
homozygous mutant (ZZ).  Homozygosity for 
the S allele was not detected in any of the DNA 
samples. 
 
The patient sample results of the genotyping 
assay were compared to the results obtained 
through IEF from an outside laboratory. Of the 
14 patient sample IEF results, 13 matched the 
real-time PCR results (Table 4).  The 
discordant sample was determined to be an 
unknown, clinically insignificant variant by 
phenotyping; our assay determined the 
genotype was heterozygous (non-S, non-Z)Z.  
Genotyping results for all 20 Mayo Clinic 
samples were found to be concordant with the 
independently determined genotypes. All 
control samples gave expected results. 
 
Discussion 
 
In this study, we evaluated a real time PCR 
method for genotyping AAT in patients being 
screened to confirm or rule-out a diagnosis of 
AAT deficiency.  Genotyping of the SERPINA1 
gene is important in the algorithms used to 
diagnose AAT deficiency, and can reduce the 
need for costly IEF or sequencing assays [18].  
Determination of serum AAT concentration is 
not sufficient as a diagnostic test for AAT 
deficiency because AAT is an acute phase 
reactant, and as such may be elevated under 
circumstances of inflammation, leading to 
incorrect measurement of baseline concen-
trations in whole blood. Levels typically remain 
well below the normal range in AAT deficient 
individuals. In addition, specific genetic 
variations, independent of the serum 
concentration, can be critical to the patient’s 
risk for developing COPD and liver disease.  
 
Currently, clinical testing for AAT deficiency 
involves four methods that are commonly used 
Table 2.  Primers and Probes for the ABI 
7500 AAT Pi*Z assay 
Forward: TCCAGGCCGTGCATAAGG 
Reverse: GCCCCAGCAGCTTCAG 
WT Probe (VIC):   CCATCGACGAGAAAG 
MUT Probe (FAM):   CATCGACAAGAAAG 
 
Table 3. DNA dilution series 
 PI*Z (CT) PI*S (CT) 
5 ng/µl 31.15 26.78 
10 ng/µl 29.2 25.63 
15 ng/µl 29.03 26.44 
20 ng/µl 28.81 24.34 
50 ng/µl 27.7 23.99 
100 ng/ul 27.12 24.12 
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to diagnose AAT deficiency: (1) measurement 
of the serum or plasma protein level, (2) AAT 
protein phenotyping from serum or plasma, (3) 
AAT genotyping, and (4) evaluation of AAT 
protein function. The measurement of 
circulating AAT levels is performed in many 
clinical laboratories as an initial screening test. 
The limitations associated with this type of 
testing include the test’s inability to detect 
individuals who are heterozygous for a 
deficiency allele and those individuals who 
often have levels at or near the normal cutoff 
value.  Phenotpying and/or genotyping are 
recommended when the AAT protein level is 
below the normal range. 
 
Protein phenotyping is performed by isoelectric 
focusing gel electrophoresis to detect the 
isoform patterns of the AAT protein. The 
limitations of this approach are its inability to 
identify PI*Null alleles due to the absence of 
circulating protein and that this procedure is 
usually performed in specialized laboratories.  
Genotyping assays are designed for the 
molecular identification of the most common 
abnormal AAT variants (PI*S and PI*Z) and 
 
Table 4. IEF comparison to genotyping results 
Lab # Phenotyping Result Protein Result PCR Result 
8 MZ 199 mg/dL (Non-S, non-Z)Z 
10 MM 139  mg/dL Non-S, non-Z 
11 MM 136 mg/dL Non-S, non-Z 
14 MM 189 mg/dL Non-S, non-Z 
16 MM 112 mg/dL Non-S, non-Z 
17 MM 168 mg/dL Non-S, non-Z 
18 MM 123 mg/dL Non-S, non-Z 
19 MM 175 mg/dL Non-S, non-Z 
20 MM 183 mg/dL Non-S, non-Z 
21 MM 179 mg/dL Non-S, non-Z 
24 MM 148 mg/dL Non-S, non-Z 
25 MM 145 mg/dL Non-S, non-Z 
26 MS 131 mg/dL (Non-S, non-Z)S 
27 M/? 81 mg/dL (Non-S, non-Z)Z 
 
Figure 1: Allelic discrimination plot for real time PCR results detecting the homozygous mutant PI*Z, 
heterozygous PI*Z and homozygous non-S/non-Z alleles. 
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thus can miss one of the more than 30 rare 
genetic variants that lead to reduced protein 
levels, absent protein levels, or normal levels 
of a dysfunctional protein.  It is for this reason 
we used the terms “non-S” and “non-Z” for our 
results; the genotyping assay cannot 
determine if a variation in the gene sequence 
exists outside the area being tested. 
 
In order to optimize testing for AAT deficiency, 
a combination of genotyping of SERPINA1 and 
measurement of serum AAT protein 
concentration provides a very informative and 
less expensive method for determining 
disease status in a patient. Patients with an 
abnormally low serum AAT protein 
concentration, yet normal genotyping results, 
may be subsequently submitted for IEF or 
sequencing studies, since this genotyping 
assay only genotypes the PI*S and the PI*Z 
mutants.  Phenotyping can identify many more 
alleles than genotyping yet is not capable of 
detecting null alleles.  The genetic status of 
any given patient becomes critical when 
deciding on screening mechanisms for other 
family members who may be at risk for 
developing disease or being a carrier of a 
variant. 
 
All patients in this study had normal levels of 
serum AAT protein with the exception of one 
patient whose level was approximately 75% of 
normal.  Interestingly, it was this same sample 
that was found to have an indeterminate 
phenotype.  Our genotyping assay was able to 
resolve this result and determine that the 
patient was heterozygous (non-S, non-Z )Z.  
This result highlights the utility of this assay, 
however, further studies need to be conducted 
with larger patient sample sizes to validate 
these findings. 
 
AAT deficiency continues to be underdiag-
nosed, especially in many patients with COPD 
where approximately 1% of these patients 
have AAT deficiency [17].  The underdiagnosis 
of AAT has been in part attributed to the 
perceived risks associated with testing for a 
genetic condition and informed consent for 
such testing [19]. Testing for AAT deficiency 
has been recommended for all patients with 
COPD, asthma with irreversible airflow 
obstruction, unexplained liver disease, or 
necrotizing panniculitis [20]. 
 
Conclusion 
AAT deficiency is often unrecognized and may 
lead to COPD and severe liver disease. AAT 
deficiency can be readily diagnosed by 
measurement of the serum or plasma protein 
level, which should be confirmed by assessing 
the genotype or protein phenotype when AAT 
levels are below the normal range. The 
method for genotyping the SERPINA1 gene 
described in this study provides a significant 
cost advantage compared to IEF for labs that 
must send samples out for analysis.  The 
combined use of AAT serum level and 
genotyping is sufficient to characterize the 
majority of normal, carrier, and affect cases 
[18]. Some cases, however, will require IEF 
reflex testing, because this assay has a very 
short turn around time; it can be performed to 
determine if IEF is necessary. 
 
Please address correspondences to: Gregory J. 
Tsongalis, PhD, Department of Pathology,  
Dartmouth Hitchcock Medical Center, One Medical 
Center Drive, Lebanon, NH 03756, Tel: 603-650-
5498, E-mail: gregory.j.tsongalis@hitchcock.org 
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